Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia Life Science Investing
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era Life Science Investing
PharmaTher Expands PharmaPatch Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs Life Science Investing
Cizzle Brands Announces That CWENCH Hydration Has Become the Official Sports Drink of USA Lacrosse Biotech Investing
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval Life Science Investing
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways Life Science Investing
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy Life Science Investing
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 Life Science Investing
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium Life Science Investing
